← boardnext 2027-02
ABCL
AbCellera Biologics Inc.distress 3/10 · well-funded / low risk$5.700%today-30% from 52w high
Lead: Vasomotor Symptoms Associated With Menopause
Revenue
pre-revenue
Liquidity
$77M
Runway
0.5 yrs
Shares 1y
+2%
Price & events
+22.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-7.4%
1W
+1.3%
1M
+40.8%
3M
+34.5%
6M
+14.3%
1Y
+83.9%
2Y
-63.9%
5Y
-85.4%
All
Overview
- Market Cap
- $1.74B
- Volume
- 324.85K
- 52 Week Range
- $2.78 – $8.12
- Total Shares
- 305.38M
- Float Shares
- 205.09M
- Short %
- 20.61%
- % Held by Insiders
- 23.04%
- % Held by Institutions
- 42.57%
- RVOL
- 0.05x
- Beta
- 1.15
Pipeline stages · 1 programs
ABCL635
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 1/2 | ABCL635 | Vasomotor Symptoms Associated With Menopause, Healthy Volunteers | — | active not recruiting |
Catalyst news & presentations · 5
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-17partnershipTCE multispecific antibodies · Preclinical research collaboration, option and license agreement for multiple GI cancers and solid tumors.SEC 8-K
- January 12, 2026enrollment completesecondaryPhase 1/2ABCL635 · First patients dosed in the Phase 2 portion of the ongoing Phase 1/2 clinical trial.SEC 8-K
- 2025-12-18partnershipEntered into settlement and patent license agreement with Bruker Corporation, resolving global patent litigation.SEC 8-K
- 2025-05-30fda agreementABCL575 · Health Canada authorized Clinical Trial Application (CTA) for ABCL575 targeting OX40L for moderate-to-severe atopic dermatitisSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+84% upside) · 8 analysts
- 2026-07-07BenchmarkHold → Buy
- 2026-05-05Cantor FitzgeraldOverweight
- 2026-04-10Jones TradingBuy
- 2025-11-07Leerink PartnersOutperform → Market Perform
- 2025-08-08StifelBuy
- 2025-07-14KeybancOverweight
Competitors — Vasomotor Symptoms Associated With Menopause
- none identified
Recent news
- 2026-07-23ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits
- 2026-07-23Abcellera Biologics, Inc. (ABCL) Q2 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Abcellera Biologics, Inc. (8QQ) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Abcellera Biologics, Inc. (8QQ) Q4 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-20Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL? - simplywall.st
- 2026-07-18ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.